Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Adjuvant for vaccine, vaccine composition containing adjuvant and application of vaccine composition

A vaccine composition and adjuvant technology, which is applied in the direction of drug combination, medical preparations containing active ingredients, bacterial antigen components, etc., can solve the needs of the development of new vaccines, the variability of aluminum glue vaccines, and the impact on the nervous system To achieve the effect of long-lasting antibody, stable effect and less frequency of immunization

Active Publication Date: 2017-02-22
PU LIKE BIO ENG
View PDF16 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are many types of immune adjuvants studied, such as aluminum gel, oil adjuvant, Freund's adjuvant, microorganisms and their metabolites, nucleic acids and their analogs, cytokines, liposomes, etc. (Dey AK, Srivastava IK.Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. Expert review of vaccines, 2011, 10: 227-251), but it is difficult to be practically applied due to some inevitable defects such as different degrees of toxic side effects or safety hazards (Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Current opinion inimmunology, 2010, 22(3): 411-416; Batista-Duharte A, Lindblad EB, Oviedo-Orta E. Progress in understanding adjuvant immunotoxicity mechanisms. Toxicology letters ,2011,203(2):97-105), these adjuvants are far from meeting the needs of new vaccine development
In particular, a large number of clinical immunization trials believe that aluminum colloidal adjuvant has some problems: (1) it has a strong stimulating effect on Th2-mediated humoral immune response, but has a weak effect on Th1-mediated cellular immune response, only Suitable for vaccines with antibodies as the main protective immunity (Exley C, Siesjo P, Eriksson H. The immunobiology of aluminum adjuvants: how do they really work? Trends in immunology, 2010, 31:103-109); (2) can Promote the production of IgE antibodies, and easily induce allergic reactions in the body; (3) local reactions may form granulomas, and very few local aseptic abscesses may occur; (4) due to their physical and chemical properties, aluminum-containing gel vaccines are afraid of freezing The post-alumina vaccine is prone to denaturation; (5) may have an impact on human and animal nervous systems (seeing Chinese patent CN101402666A)
Moreover, during clinical application, it is found that the phenomenon of body temperature rise after the existing commercialized vaccine immunizes pigs, and other related vaccines in the prior art also have similar reports such as Chinese patents CN103194413A, CN104312964A

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adjuvant for vaccine, vaccine composition containing adjuvant and application of vaccine composition
  • Adjuvant for vaccine, vaccine composition containing adjuvant and application of vaccine composition
  • Adjuvant for vaccine, vaccine composition containing adjuvant and application of vaccine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0034] As an embodiment of the present invention, in the vaccine composition of the present invention, the aluminum gel content is 8%-20% V / V, and the chitosan concentration is 1-5 mg / ml.

[0035] As a preferred embodiment of the present invention, in the vaccine composition of the present invention, the aluminum gel is 8%-20% V / V, the chitosan is 1-5mg / ml, and the lecithin concentration is 0.5-5mg / ml. ml.

[0036] As an embodiment of the present invention, in the vaccine composition of the present invention, the antigens include Mycoplasma hyopneumoniae antigen, Haemophilus parasuis antigen, Pasteurella multocida antigen, Streptococcus suis antigen, grapevine Bacillus antigen, Bordetella bronchiseptica antigen, Actinobacillus lobar pneumonia antigen, Escherichia coli antigen, Bordetella bronchiseptica antigen and toxigenic Pasteurella multocida antigen, Salmonella choleraesuis antigen, Salmonella enteritidis antigen, One or more of Erysipelothrix rhusiopathiae antigen, Mycop...

Embodiment 1

[0054] The preparation of embodiment 1 antigen

[0055] 1.1 Preparation of Mycoplasma hyopneumoniae antigen

[0056] According to the Chinese patent CN103083655A, the bacterial liquid of Mycoplasma hyopneumoniae HN0613 strain was prepared and the content of bacterial liquid was determined, and the result: the content of Mycoplasma hyopneumoniae strain HN0613 was 1×10 9 CCU / ml; and inactivate and test the bacterial liquid, the result: the coloring of the medium does not change, and the pH value of the medium does not decrease, indicating that the bacterial liquid of Mycoplasma hyopneumoniae HN0613 strain is successfully inactivated.

[0057] 1.2 Preparation of Haemophilus parasuis antigen

[0058] According to Chinese patent CN103083655A, respectively prepare Haemophilus parasuis type 4 JS strain and type 5 ZJ strain bacterial liquid and measure the bacterial liquid content, the result: the contents of Haemophilus parasuis type 4 JS strain and type 5 ZJ strain are both 5× 10 ...

Embodiment 2

[0059] The preparation of embodiment 2 adjuvants

[0060] Aluminum glue: purchased from General Chemical, LLC of the United States HPA adjuvant.

[0061] Chitosan mother liquor: the chitosan purchased from Qingdao Haihui Biological Engineering Co., Ltd. (molecular weight is 145kD, and the deacetylation degree is 50%) is completely dissolved in 1% V / V acetic acid aqueous solution and is prepared with a concentration of 15mg / ml Chitosan acetic acid solution, adjust the solution to pH 7.4 with NaOH, and carry out filter sterilization to obtain 15mg / ml chitosan mother liquor.

[0062] Lecithin mother liquor: Dissolve 1 g of lecithin purchased from Beijing Yuanhuamei Phospholipid Technology Co., Ltd. with ethanol, add PBS solution and mix evenly, then conduct vacuum distillation. Steam sterilize at -125°C for 30 minutes, stir twice with ultrasonic waves, 10 minutes each time, add PBS solution to 100ml, and perform filter sterilization to obtain 10mg / ml lecithin mother liquor.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an adjuvant for a vaccine. The adjuvant is prepared from alumina gel, chitosan and lecithin. The invention further discloses vaccine composition containing the adjuvant and an application of the vaccine composition. The adjuvant can make an organism produce effective humoral immunity when used for the inactivated vaccine, cannot cause body temperature rise and side effects and can have better immune response during lower antigen content and single immunity.

Description

technical field [0001] The invention belongs to the technical field of veterinary biological products, and in particular relates to an adjuvant for enhancing antigen immune response. Background technique [0002] Bacterial, viral, and parasitic infections are widespread in humans and animals, and diseases caused by these infectious agents are often resistant to antimicrobial pharmaceutical therapies, leaving no effective treatment. Therefore, vaccinology methods are more commonly used in this field to control infection, specifically by using live pathogens, inactivated pathogens or their products, or preparing pathogen protein subunits into vaccines through genetic engineering, and conducting vaccination to induce infection. specific immunity. However, certain antigens do not produce sufficient stimulation of the immune system when administered alone. Therefore, it is necessary to add an immune adjuvant that can increase the immune response of the body to obtain a sufficie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/02A61K39/102A61P31/04A61P11/00
Inventor 张许科孙进忠王莹田克恭
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com